These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25090819)

  • 1. Can zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 4 infected Egyptian patients?
    Mohamed AA; Abbassi MM; Hamed WA; EzzEl-Arab MA; Aref AM
    Acta Gastroenterol Belg; 2014 Jun; 77(2):217-23. PubMed ID: 25090819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
    El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
    J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
    Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
    Ibrahim M; Gomaa W; Ibrahim Y; El Hadad H; Shatat M; Aleem AA; Essawy M; Fouad YM
    J Gastrointestin Liver Dis; 2010 Dec; 19(4):387-92. PubMed ID: 21188329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
    Furusyo N; Ogawa E; Murata M; Toyoda K; Ohnishi H; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Kainuma M; Okada K; Hayashi J
    J Antimicrob Chemother; 2014 Feb; 69(2):483-90. PubMed ID: 24092661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M; Ouzan D; Rosenheim M; Doffoël M; Marcellin P; Pawlotsky JM; Salomon L; Fagnani F; Rouanet S; Pinta A; Vray M
    Antivir Ther; 2012; 17(1):101-10. PubMed ID: 22267474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    Saad Y; Ahmed A; Saleh DA; Doss W
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.
    Nishikawa H; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Kita R; Kimura T; Osaki Y
    BMC Res Notes; 2012 Mar; 5():135. PubMed ID: 22405406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.